Stocktoria
Oruka Therapeutics, Inc. ORKA
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2000-07-21
Oruka Therapeutics, Inc. financials (annual)
Bars are annual figures from 2015 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $100.6M | $1.0M | $4.7M | $13.8M | $5.0M | $1.8M | $4.2M | $14.1M | $12.3M | $7.1M |
| Operating income | -$122.1M | -$7.3M | -$10.6M | -$19.3M | -$9.8M | -$5.8M | -$8.1M | -$18.7M | -$16.6M | -$11.5M |
| Interest expense | — | — | — | — | $9,000 | $7,000 | $8,000 | $6,000 | — | $4,000 |
| Income tax | — | $0 | $0 | $0 | -$9,000 | -$167,000 | -$31,000 | -$61,000 | $0 | $0 |
| Net income | -$105.4M | -$5.3M | -$9.9M | -$19.3M | -$9.7M | -$5.5M | -$7.9M | -$18.5M | -$16.4M | -$11.4M |
| EPS (diluted) | — | $-0.37 | $-0.69 | $-1.39 | — | — | — | — | — | — |
| Operating cash flow | -$88.2M | -$5.0M | -$10.9M | -$18.8M | -$7.7M | -$4.8M | -$8.2M | -$17.5M | -$15.0M | -$10.5M |
| Free cash flow | -$88.4M | -$5.0M | -$10.9M | -$18.8M | -$7.7M | -$4.8M | -$8.2M | -$17.5M | -$15.0M | -$10.5M |
| Cash & equivalents | $46.9M | $37.4M | $42.4M | $53.4M | $49.1M | $8.4M | $6.6M | $8.7M | $7.4M | $38.8M |
| Total assets | $488.6M | $37.9M | $43.1M | $54.9M | $50.4M | $8.5M | $6.8M | $12.4M | $24.6M | $39.6M |
| Total liabilities | $16.7M | $841,000 | $1.4M | $3.9M | $3.9M | $926,000 | $793,000 | $2.1M | $2.4M | $1.5M |
| Shareholders' equity | $471.9M | $37.0M | $41.7M | $51.0M | $46.5M | $7.6M | $6.0M | $10.3M | $22.2M | $38.1M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.